Clinical trials: Etoposide, completed
Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00005964
- Testing
- filgrastim, cyclophosphamide, doxorubicin hydrochloride
- Where
- 47 sites in United States
- Volunteers
- 59 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Trial name
- NCT00006012
- Testing
- filgrastim, amifostine trihydrate, cisplatin
- Where
- 84 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin, irinotecan, carboplatin, and etoposide, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00072527
- Testing
- carboplatin, cisplatin, etoposide
- Where
- 76 sites in United States
- Volunteers
- 78 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098774
- Testing
- filgrastim, rituximab, cytarabine
- Where
- 30 sites in United States
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia
RATIONALE: Bortezomib and midostaurin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01174888
- Testing
- midostaurin, Bortezomib, mitoxantrone hydrochloride
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Alison Walker
Leukemia, Lymphoma
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002494
- Testing
- cyclophosphamide, cytarabine, dexamethasone
- Where
- 23 sites in United States
- Volunteers
- 134 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors
1. To determine the outcome of patients with potentially resectable superior sulcus tumors of non-small cell histology treated by surgery followed by accelerated radiation therapy and chemotherapy. 2.
- Trial name
- NCT00984997
- Testing
- Surgery, Chest Irradiation, Cisplatin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002768
- Testing
- filgrastim, busulfan, cytarabine
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma
Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients with relapsed…
- Trial name
- NCT00002880
- Testing
- Etoposide phosphate
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non Small Cell Lung Cancer
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
- Trial name
- PROCLAIM (NCT00686959)
- Testing
- Pemetrexed, Cisplatin, Etoposide
- Where
- 133 sites in United States, Argentina and 17 more
- Volunteers
- 598 people
- Sponsor
- Eli Lilly and Company
Extragonadal Germ Cell Tumor, Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, carboplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing them or by stopping them from dividing.
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- NCT00002558
- Testing
- filgrastim, carboplatin, etoposide
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia
Primary Objective: To determine the progression free survival (PFS) of the preparative regimen rituximab, etoposide and total body irradiation (TBI), in patients with acute lymphoblastic leukemia (ALL) receiving allogeneic…
- Trial name
- NCT00427791
- Testing
- Etoposide, Total Body Irradiation, Rituximab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer
The objective of the study is to determine if men with evidence of progressive prostate cancer while on chronic androgen ablation of ≥ 1 year duration will exhibit a clinical response following administration of parenteral…
- Trial name
- NCT01084759
- Testing
- Testosterone injection, Etoposide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Diffuse Large B-cell Lymphoma
Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
The purpose of this study is to determine the efficacy and safety of ofatumomab in combination with ICE chemotherapy in subjects with relapsed/refractory DLBCL following failure to combination rituximab and anthracycline based…
- Trial name
- DLBL (NCT02412267)
- Testing
- O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)
- Where
- Singapore
- Volunteers
- 17 people
- Sponsor
- National Cancer Centre, Singapore
Acute Myelogenous Leukemia
Lenalidomide Plus Chemotherapy for AML
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs.
- Trial name
- NCT01681537
- Testing
- Lenalidomide, Mitoxantrone, Etoposide
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Massachusetts General Hospital
Non-Small Cell Lung Cancer
Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
In a previous phase II study, patients with pathological stage IIIb (without pleural effusion) NSCLC were treated with concurrent cisplatin and etoposide plus thoracic radiotherapy followed by 3 cycles of consolidation therapy…
- Trial name
- NCT00216125
- Testing
- Cisplatin, Etoposide, Radiation
- Where
- 15 sites in United States
- Volunteers
- 243 people
- Sponsor
- Nasser Hanna, M.D.
Lymphoma
Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies
Cohort 1: Patients who are less than or equal to 65 years of age. 1. To determine the disease-free survival (DFS) in the 2 arms (standard dose versus high dose rituximab) Cohort 2: Patients who are older than 65 years of age 1.
- Trial name
- NCT00472056
- Testing
- Carmustine, Etoposide, Cytarabine
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Lymphoma
Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002766
- Testing
- dactinomycin, sargramostim, carmustine
- Where
- 7 sites in United States
- Volunteers
- 170 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non-Hodgkin's Lymphoma
Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom
To evaluate the efficacy (complete response rate) of Ybritumomab Tiuxetan (Zevalin) administration in the conditioning treatment of patients with refractory large B-cell diffuse lymphoma submitted to autologous transplantation of…
- Trial name
- Z-BEAM LDGGB (NCT00646750)
- Testing
- Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)
- Where
- 18 sites in Spain
- Volunteers
- 31 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Lymphoma
Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Antiviral therapy may kill viruses such as HTLV-1 that can cause cancer.
- Trial name
- NCT00041327
- Testing
- filgrastim, recombinant interferon alfa, Etoposide
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- AIDS Malignancy Consortium